Exclusive: Md. biotech kicks off Series A funding round after inking licensing deal with pharmaceutical giant


The Gaithersburg company develops RNA therapies for drug-resistant cancers and other diseases.

Previous Mount Carmel promotes finance executive to CFO; predecessor left for another system
Next Koch CFO talks growth: The National Observer Oct. 4, 2022